AcSe CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug.

Trial Profile

AcSe CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Crizotinib (Primary)
  • Indications Anaplastic large cell lymphoma; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Glioblastoma; Haematological malignancies; Liver cancer; Muscle tissue neoplasms; Neuroblastoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Rhabdomyosarcoma; Solid tumours; Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms AcSe-CRIZOTINIB
  • Most Recent Events

    • 07 Jun 2016 Interim results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 09 Sep 2015 Interim results (n=39) presented at the 16th World Conference on Lung Cancer.
    • 09 Sep 2015 Results of sub group analysis presented at the 16th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top